Company Encyclopedia
View More
name
Goldman Sachs ActiveBeta US Small Cap EQ
GSSC.US
News
View More

Fabrinet Director Makes a Strategic Stock Move

Fabrinet Director Darlene S. Knight sold 500 shares worth $236,000 on December 4, 2025. CEO Seamus Grady also sold 22.5K shares for $10M. Barclays raised Fabrinet’s price target due to strong Q1 performance and optimistic Q2 guidance. Q1 revenues hit $978M, up 22% YoY. Despite some challenges, Q2 outlook remains positive. TipRanks’ AI Analyst rates FN as Outperform, citing strong financials and positive earnings call.

Tip Ranks·
US
FN
+5.47%
Tip Ranks·
US
FN
+5.47%

Dir Knight Sells 500 ($236K) Of Fabrinet [FN]

Knight Darlene S Director of Fabrinet [FN] filed a Form 4 on December 4, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/4/25TransactionSaleShares500Price$472.00Value$236,000Ending Holdings: 3,184 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Reuters·
US
FN
+5.47%
Reuters·
US
FN
+5.47%

Fabrinet Director Darlene S. Knight Reports Sale of Common Shares

Darlene S. Knight, a Director at Fabrinet Co. Ltd., has reported the sale of common shares of the company. The information was published via EDGAR by the U.S. Securities and Exchange Commission on December 4, 2025. This news brief was generated by Public Technologies using AI and is for informational purposes only.

Reuters·
US
FN
+5.47%
Reuters·
US
FN
+5.47%

Credo Stock: The Smart Money AI Bet?

Credo Technology (NASDAQ:CRDO) has seen its stock rise over 2.5x year-to-date, driven by its role in AI infrastructure. The company's Q2 FY'26 earnings report showed a 272% revenue increase to $268 million, with net income surging over 10x. Credo's technology addresses AI connectivity challenges, positioning it as a key player in the hyperscaler market. Despite high valuation, its strong fundamentals and nearly debt-free balance sheet support its growth narrative.

Forbes·
US
CRDO
-4.37%
Forbes·
US
CRDO
-4.37%

PTC Therapeutics CEO Makes Significant Stock Sale!

PTC Therapeutics CEO Matthew B. Klein sold 3,428 shares worth $271,051 on December 3, 2025. The company has seen significant stock activity due to strong Q3 earnings and the launch of Sephience. RBC Capital downgraded the stock, while Goldman Sachs and TD Cowen raised their price targets. Despite challenges, the earnings call was positive. TipRanks’ AI Analyst rates PTCT as Outperform, citing strong technical indicators and favorable valuation.

Tip Ranks·
US
PTCT
+2.76%
Tip Ranks·
US
PTCT
+2.76%
© 2025 Longbridge｜Disclaimer